Navigation Links
Genzyme Files Applications for Approval of Mozobil in the United States and Europe
Date:6/17/2008

han drug status in the United States and European Union and the pivotal trials have undergone Special Protocol Assessment by the FDA and Protocol Assistance by the EMEA. Genzyme has been developing Mozobil since its acquisition of AnorMED, Inc. in 2006.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

Genzyme(R) and AnorMED(R) are registered trademarks of Genzyme Corporation or its subsidiaries. Mozobil(TM) is an unregistered trademark of Genzyme Corporation or its subsidiaries. All rights reserved.

This press release contains forward-looking statements, including the statements regarding: the anticipated timing of product approvals in the U.S. and Europe, the anticipated timing of filing additional applications for approval in other countries, the potential adoption of Mozobil in the marketplace, the potential benefits to different types of patients, commercial launch plans and Mozobil's potential use in other therapeutic applications. T
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genzyme Boosts Quality Using Dyadem Quality Lifecycle Management
2. Awareness of Genzymes Renvela(R) (Sevelamer Carbonate) is High, Although Uptake of this New Phosphate Binding Agent has Been Slower than Nephrologists and Renal Dietitians Initially Expected
3. Genzyme Reports Strong First-Quarter Growth
4. Genzyme to Build New R&D Center in Beijing
5. Genzyme Provides Update on Myozyme(R) Manufacturing
6. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
7. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
8. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
9. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
10. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
11. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management ... Product Strategy. In this role, Michelle will work with current ... in the development of iLab products. Her main goal will ... to the scientific community by offering the most advanced, user-friendly, ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), ... solutions for patients, physicians, the biopharmaceutical industry, regulators, ... the signing of a three-year Research Collaboration Agreement ... (FDA). This initiative is designed to generate ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... TOKYO, Oct. 22 /Xinhua-PRNewswire/ -- Olympus Capital Holdings ... reached an agreement to,sell Arysta LifeScience Corporation, the ... for an enterprise value of,approximately JPY 250 billion ... for Olympus Capital, a leading middle market private,equity ...
... 21 Boston,Scientific Corporation (NYSE: BSX ) ... patients from its TAXUS ARRIVE 1 and 2 ... Express2(TM) Paclitaxel-Eluting,Coronary Stent System in "real-world" practice. The ... events and repeat,revascularization through two years in complex ...
... be Webcast as Part of AACR Virtual Meeting -, ... RGDX ) today announced that Kathleen Danenberg, the ... on the role,of pharmacogenomics in tailoring medicine at the ... will be held October 22-26, 2007 at the Moscone ...
Cached Biology Technology:Olympus Capital Announces Agreement to Sell Arysta LifeScience Corporation 2Olympus Capital Announces Agreement to Sell Arysta LifeScience Corporation 3ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 2ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 3ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 4Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 2Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 3
(Date:4/23/2014)... Aires yesterday, Argentina joins the European Molecular Biology ... move strengthens the ties between the European and ... scientists access to EMBL,s world-class facilities and programs, ... its inception, fostering excellent life science research and ... of EMBL,s mission," says EMBL Director General Iain ...
(Date:4/23/2014)... cli-fi, is a newly coined term for novels and films ... from University of Copenhagen shows how these fictions serve as ... consequences of climate change and imagine other living conditions. ... changes in the atmosphere; it is also a cultural phenomenon ... read and the films we see. And there are so ...
(Date:4/23/2014)... most comprehensive study to date of the family ... more effective vaccine strategies and reveals surprising findings ... results could alter public health strategies to control ... each year. , Genomic analysis of 343 strains ... around the world collected over the last 100 ...
Breaking Biology News(10 mins):Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3Impact of whooping cough vaccination revealed 2
... AGA Research Foundation and Horizon Pharma further establish their ... the 2013 AGA-Horizon Pharma Fellow Abstract Prizes and the ... third year, this competition continues to grow in popularity ... in basic and clinical research," said Nicholas F. LaRusso, ...
... declining worldwide and a major cause is a deadly fungus ... shows they can also die from this pathogen, contrary to ... spreads the disease. When researchers raised the frogs from ... strain of this pathogen, Batrachochytrium dendrobatidis , also called ...
... news release is available in French . ... in older mice with Alzheimer,s disease can be reversed with treatment. ... - The Neuro, at McGill University and at Universit de Montral ... brain of mice with advanced Alzheimer,s disease (AD) recovers memory and ...
Cached Biology News:Horizon Pharma Abstract Prizes recognize promising fellows and students 2Bullfrogs may help spread deadly amphibian fungus, but also die from it 2Blocking overactive receptor in Alzheimer's recovers memory loss and more 2
... RNase ONE Ribonuclease is a 27kDa periplasmic ... degradation of RNA to cyclic nucleotide monophosphate ... degradation of these intermediates to 3-NMPs (1). ... few known RNases that can cleave a ...
The Holten Safe 2010 Class II Biological Safety Cabinets provide the most ergonomical working condition of comfort while incorporating the latest technology for safety, efficiency and performance....
... HM-4000 Multidizer is designed with a variety ... rotating - all in one unit. Shake, ... independently operating compartments allow for hybridization and ... motion , The upper chamber uses ...
... is designed for paramagnetic bead precipitation from ... PCR plates with no additional accessories. The ... a standard SBS 96-well microplate footprint. The ... guarantees easy and fast (as little as ...
Biology Products: